Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and the safety of Zevalin-BEAM
preparative regimen before autologous stem cell transplantation (ASCT) as measured by the
event free survival (EFS).
The goal is to obtain a 15% increase of EFS at 2 years.